Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis; effects on frequency of acute exacerbation and all-cause hospital admission.

Edward JM Monk; Chris Harris; Rainer Döffinger; Gemma Hayes; D W Denning; Chris Kosmidis

doi:10.1136/thoraxjnl-2019-213606

Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis; effects on frequency of acute exacerbation and all-cause hospital admission.

Edward JM Monk, Chris Harris, Rainer Döffinger, Gemma Hayes, D W Denning, Chris Kosmidis

Division of Immunology, Immunity to Infection and Respiratory Medicine

Research output: Contribution to journal › Article › peer-review

338 Downloads (Pure)

Abstract

Chronic pulmonary aspergillosis (CPA) is often poorly responsive to antifungal treatment; secondary infections increase morbidity/mortality, particularly in progressive cases. Interferon gamma (IFNγ) has been implicated in not only Aspergillus control but also bacterial clearance. Clinical notes of patients with CPA treated with IFNγ (2011-2018) were retrospectively hand-searched. In patients treated for >12 months (n=20), the frequency of acute exacerbation reduced from 3.1 to 1.4 episodes/year (p=0.006) in the 12 months after treatment initiation compared to the 12 months before. A significant reduction in the frequency of hospital admissions/year was also observed (0.8 to 0.3, p=0.04). These findings support further prospective studies.

Original language	English
Journal	Thorax
Early online date	30 Mar 2020
DOIs	https://doi.org/10.1136/thoraxjnl-2019-213606
Publication status	Published - 2020

Keywords

Immunodeficiency
chronic pulmonary aspergillosis
Respiratory Infection
interferon-gamma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/thoraxjnl-2019-213606

Thorax Manuscript R2Accepted author manuscript, 40.9 KB
thorax IFNg 2020Accepted author manuscript, 418 KB

MFIG: Manchester Fungal Infection Group (MFIG)
Bromley, M. (PI), Bertuzzi, M. (PI), Gago, S. (PI), Denning, D. (PI), Kosmidis, C. (PI), Bowyer, P. (PI), Amich Elias, J. (PI), Richardson, M. (PI), Richardson, R. (PI), Van Rhijn, N. (PI) & Bottery, M. (PI)
15/08/13 → …
Project: Research

Cite this

@article{1489af69d0f24743aa1c57dbd1ff0142,

title = "Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis; effects on frequency of acute exacerbation and all-cause hospital admission.",

abstract = "Chronic pulmonary aspergillosis (CPA) is often poorly responsive to antifungal treatment; secondary infections increase morbidity/mortality, particularly in progressive cases. Interferon gamma (IFNγ) has been implicated in not only Aspergillus control but also bacterial clearance. Clinical notes of patients with CPA treated with IFNγ (2011-2018) were retrospectively hand-searched. In patients treated for >12 months (n=20), the frequency of acute exacerbation reduced from 3.1 to 1.4 episodes/year (p=0.006) in the 12 months after treatment initiation compared to the 12 months before. A significant reduction in the frequency of hospital admissions/year was also observed (0.8 to 0.3, p=0.04). These findings support further prospective studies.",

keywords = "Immunodeficiency, chronic pulmonary aspergillosis, Respiratory Infection, interferon-gamma",

author = "Monk, {Edward JM} and Chris Harris and Rainer D{\"o}ffinger and Gemma Hayes and Denning, {D W} and Chris Kosmidis",

year = "2020",

doi = "10.1136/thoraxjnl-2019-213606",

language = "English",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ ",

}

TY - JOUR

T1 - Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis; effects on frequency of acute exacerbation and all-cause hospital admission.

AU - Monk, Edward JM

AU - Harris, Chris

AU - Döffinger, Rainer

AU - Hayes, Gemma

AU - Denning, D W

AU - Kosmidis, Chris

PY - 2020

Y1 - 2020

N2 - Chronic pulmonary aspergillosis (CPA) is often poorly responsive to antifungal treatment; secondary infections increase morbidity/mortality, particularly in progressive cases. Interferon gamma (IFNγ) has been implicated in not only Aspergillus control but also bacterial clearance. Clinical notes of patients with CPA treated with IFNγ (2011-2018) were retrospectively hand-searched. In patients treated for >12 months (n=20), the frequency of acute exacerbation reduced from 3.1 to 1.4 episodes/year (p=0.006) in the 12 months after treatment initiation compared to the 12 months before. A significant reduction in the frequency of hospital admissions/year was also observed (0.8 to 0.3, p=0.04). These findings support further prospective studies.

AB - Chronic pulmonary aspergillosis (CPA) is often poorly responsive to antifungal treatment; secondary infections increase morbidity/mortality, particularly in progressive cases. Interferon gamma (IFNγ) has been implicated in not only Aspergillus control but also bacterial clearance. Clinical notes of patients with CPA treated with IFNγ (2011-2018) were retrospectively hand-searched. In patients treated for >12 months (n=20), the frequency of acute exacerbation reduced from 3.1 to 1.4 episodes/year (p=0.006) in the 12 months after treatment initiation compared to the 12 months before. A significant reduction in the frequency of hospital admissions/year was also observed (0.8 to 0.3, p=0.04). These findings support further prospective studies.

KW - Immunodeficiency

KW - chronic pulmonary aspergillosis

KW - Respiratory Infection

KW - interferon-gamma

U2 - 10.1136/thoraxjnl-2019-213606

DO - 10.1136/thoraxjnl-2019-213606

M3 - Article

SN - 0040-6376

JO - Thorax

JF - Thorax

ER -

Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis; effects on frequency of acute exacerbation and all-cause hospital admission.

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Projects

MFIG: Manchester Fungal Infection Group (MFIG)

Cite this